RE:RE:RE:Sobering statistics in oncology trials would be nice if the company gave a timely trial update to keep building on the current price momentum. The apathy shown by the the company towards the share price seems well entrenched. All they would have to do is update current enrolment and current dosing level and timelines of more data release.
SPCEO1 wrote: I suspect the fact the trial appears to be still ongoing mitigates the risk of problems related to the overaccumulation in healthy cells expressing sortilin. We are probably in the clear on that risk.
jeffm34 wrote: it has a couple things going for it which will increase the odds of success greatly. They are using Docetaxel which already works and is approved. It doesn't even have to be more effective than Docetaxel alone. If it's only just as effective but at a lower dose meaning less side effects then it will still be approved. The only wild card is over accumulation in healthy cells expressing sortilin.
palinc2000 wrote: Very low [3.8%] success rate.....I fail to see any known hard facts in our own Phase 1 apart that it is still ongoing and dosing levels have increased but to unknown levels.What dont I get? Would love to get excited but I see nothing except hope
https://www.acsh.org/news/2020/06/11/clinical-trial-success-rates-phase-and-therapeutic-area-14845